| Literature DB >> 26121106 |
K Kudo1, H Muramatsu2, N Yoshida3, R Kobayashi4, H Yabe5, K Tabuchi6, K Kato3, K Koh8, Y Takahashi2, Y Hashii9, Y Kawano10, M Inoue11, Y Cho12, H Sakamaki13, K Kawa14, K Kato3, R Suzuki15, S Kojima2.
Abstract
The outcome of 55 children with severe aplastic anemia (SAA) who received a second hematopoietic stem cell transplantation (HSCT) was retrospectively analyzed using the registration data of the Japanese Society for Hematopoietic Cell Transplantation. The 5-year overall survival (OS) and failure-free survival (FFS) after the second transplantation were 82.9% (95% confidence interval (CI), 69.7-90.8)) and 81.2% (95% CI, 67.8-89.4), respectively. FFS was significantly better when the interval between the first and second transplantation was >60 days (88.9%; 95% CI, 73.0-95.7) than when it was ⩽60 days (61.4%; 95% CI, 33.3-80.5; P=0.026). All 12 patients who were conditioned with regimens containing fludarabine and melphalan were alive with hematopoietic recovery. These findings justify the recommendation of a second HSCT for children with SAA who have experienced graft failure after first HSCT.Entities:
Mesh：
Year: 2015 PMID： 26121106 DOI： 10.1038/bmt.2015.153
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483